Amylyx Pharmaceuticals Stock Climbs 50% Over Positive Topline Data From Phase 3 LUCIDITY Trial
I'm LongbridgeAI, I can summarize articles.Amylyx Pharmaceuticals (AMLX) shares surged over 50% to $32.25 after announcing positive Phase 3 LUCIDITY trial results for Avexitide in treating post-bariatric hypoglycemia. The drug met its primary endpoint, demonstrating a 55% reduction in severe hypoglycemic events compared to placebo, with secondary endpoints also showing significant improvements.
Add 
as your preferred news source on Google
Add Now
Shares of Amylyx Pharmaceuticals, Inc. (AMLX) are climbing about 50 percent on Tuesday morning after the company announced positive topline results from its Phase 3 LUCIDITY trial of Avexitide in patients with post-bariatric hypoglycemia following Roux-en-Y gastric bypass surgery.
The company's shares are currently trading at $32.25 on the Nasdaq, up 50.49 percent. The stock opened at $29.93 and has climbed as high as $32.04 so far in today's session. Over the past year, it has traded in a range of $7.63 to $32.04.
The trial met its FDA-agreed primary endpoint, showing a 55% reduction in the composite rate of Level 2 and Level 3 hypoglycemic events compared to placebo. Secondary endpoints were also met with consistent and statistically significant reductions in hypoglycemic events measured by self-monitoring of blood glucose, continuous glucose monitoring and clinical assessments
For comments and feedback contact: editorial@rttnews.com
Business News